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ABSTRACT 
 
Introduction 
Lead poisoning is a serious public health issue that has gained intense attention due to the discovery of 
excessive amounts of lead in the drinking water in Flint, Michigan. Although treatment recommendations 
are updated continuously, the medications for lead chelation therapy have not changed substantially for 
decades. In addition, the current agents have limitations. Therefore, an orally bioavailable novel compound, 
named C2E2 (diethyl ester of diethylenetriaminepentaacetic acid), may offer a new treatment option for the 
management of large populations affected by lead contamination. In order to establish a dosing regimen for 
C2E2 for treatment of lead toxicity, the binding property of C2E2 for lead must be first measured in a series 
of laboratory experiments. Objective: To assess the binding affinity of C2E2 for lead at 5 µg/dL, 45 µg/dL, 
and 80 µg/dL blood lead levels and in comparison to DTPA. 
 
Methods 
A series of centrifugation and filtration steps separated the samples into three fractions: C2E2-bound lead, 
protein-bound lead, and free lead. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) then 
measured the lead content of each fraction, which allowed the creation of binding affinity curves via Gauss-
Newton non-linear least squares regression analysis. 
 
Results 
Percentage recoveries for 5 µg/dL, 45 µg/dL, and 80 µg/dL blood lead concentrations with C2E2 were 
804%, 295%, and 203%, respectively. The percentage recovery for DTPA was 14.3% with one hour 
incubation. The percentage recovery for C2E2 was 20.5% and 15.7% with one hour and four hours of 
incubations. 
 
Conclusions 
The binding profiles for C2E2 and DTPA did not show competitive binding relationships, as indicated by 
arbitrarily high or very low percentage recoveries of lead. These results suggest that further in vitro 
experiential analysis is required at a much higher concentration of lead. This study represents the initial 
step of a larger investigation to optimize dosing regimen for C2E2 by constructing a pharmacokinetic model 
and to update the pharmacological treatment protocols for lead poisoning.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1. INTRODUCTION 
 
1.1 Background 
 
Recent large-scale lead contamination incidents, such as the Flint water crisis, have raised public concerns 
over potentially detrimental effects of lead exposure and have spurred research interest in the 
pharmacological treatment of lead poisoning. Lead is a naturally occurring element that has been widely 
used in a variety of consumer products, such as batteries, ceramics, cosmetics, gasoline, lead-based paints, 
pipes, plumbing materials, and solders. However, lead is also a neurotoxin that can accumulated and be 
stored in the human body which may cause long-term toxicities, especially in children under the age of six 
years old.1 Since the 1980s, the primary focus to reduce lead poisoning has been through prevention. Federal 
and state agencies monitor population blood lead levels intermittently and updated relevant guidelines to 
control lead levels in the air, soil, water, consumer products, and occupational settings.2 Historically, 
impactful regulations include banning leaded gasoline in 1975 and lead-based paints in 1978.3  
 
Although national surveillance and regulations of environmental lead levels are well in place, the 
2014 Flint water crisis still occurred resulting in the declaration of a federal emergency. This incidence 
raised concerns nation-wide over lead toxicity, which resurfaced as a threat to the public’s health. Over 
100,000 Flint residents were potentially exposed to improperly treated water that had concentrations of lead 
much higher than established national standards.4 A study revealed that the percentage of children with 
elevated blood lead levels raised from 2.4% to 4.9% before and after the Flint water crisis.4 Exposure to 
high concentrations of lead can cause irreversible adverse effects and even death. 2, 5 Developing brains and 
organ systems in young children are especially vulnerable. Children under the age of six have the highest 
risk for suffering long-term health consequences, neurologically and behaviorally.6 After entering the body, 
lead is redistributed to many vital organs including the brain, kidneys, and liver, and can accumulate and 
be stored for decades in teeth and bones. Exposure to lead may cause both acute and chronic damages to 
the immunological, hematological, and cardiovascular systems, and neurotoxicity, nephrotoxicity, and 
reproductive toxicity are possible as well.1  
 
Although, there is no established safe level of lead, the CDC currently references an elevated blood 
lead level (BLL) as greater than or equal to 5 micrograms per deciliter (µg/dL) for adults, pregnant women, 
and children. 5, 6, 7, 8 NIOSH designated the reference BLL as 5 µg/dL.9 This was lowered from 10 µg/dL 
due to researches showing increased risk of subsequently developing hypertension, renal toxicity, and 
cognitive and reproductive dysfunctions as a result of slow, cumulative exposures. The Association of 
Occupational and Environmental Clinics (AOEC) Medical Management Guidelines for Lead-Exposed 
Adults strongly recommends to consider chelation therapy in adults with BLLs above 80 µg/dL and 
showing significant signs and symptoms of toxicity, and for those who are at high risk for long-term 
cumulative exposure.10, 11  
 
Additionally, chelation therapy is recommended for children with a BLL of greater than or equal 
to 45 µg/dL.12 Children under the age of six years old not only tend to absorb more lead, but are also more 
sensitive to lead toxicity than adults. The Environmental Protection Agency (EPA) and the CDC emphasize 
that even low BLLs in children can result in behavioral and learning problems, slowed growth, hyperactivity, 
lower intelligence, poor academic achievement, and poorer quality of life in adulthood.1, 6 The CDC 
estimates about half a million children in the United States have elevated BLLs higher 5 µg/dL, and at least 
four million households have children who are exposed to high levels of lead.6 Furthermore, lead exposure 
can be substantially more detrimental in pregnant women. During pregnancy, stored lead can remobilize 
into the circulation and cross the placenta. Maternal lead exposure prior to or during pregnancy may result 
in harm to the developing fetus and the effects may takes years to appear.13 The 2010 National Health and 
Nutrition Examination Survey estimated that almost 1% of women in childbearing ages between 15 to 44 
have BLLs greater than or equal to 5 µg/dL.8  
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The Flint water disaster also brought the safety and efficacy of current lead chelation therapies to 
the public’s attention.4 Currently, there is no evidence-based guidance to chelation therapy due to lack of 
relevant studies.13 Existing recommendations also lack consistence and are outdated. For decades, the 
primary management to keep population BLL less than 5 µg/dL (10 µg/dL prior to 2015) has been 
preventive, including removal from the source, reducing exposure, and preventing entry. However, we may 
need alternative strategies for acute management of large populations who are potentially affected by lead. 
Since chelation therapy is not used unless the BLL is greater than 80 µg/dL, which may occur years after 
exposure, by the time these people begin to show toxicity, it may already be too late to reverse the 
damages.11 Unfortunately, the likelihood of another population-wide lead intoxication may be greater than 
anticipated. Studies have showed that lead contamination problems extend beyond Flint, Michigan. A 
recent EPA analysis revealed that between 2012 and 2015, around 350 school and daycare centers failed 
lead tests approximately 470 times.14 These children may have already been exposed to too much lead even 
under existing preventive strategies. In preparation for future large-scale lead contamination, it is essential 
to determine efficacious medical therapy ready to treat many people, quickly and safely. 
 
Current lead chelation therapies utilize injectable, oral or a combination of injectable and oral 
medications for moderate to severe intoxications depending on the BLL.10 Two FDA approved chelating 
agents for the treatment of lead poisoning are calcium disodium ethylenediaminetetraacetate (CaNa2EDTA) 
and meso 2,3-dimercapto-succinic acid (DMSA).15 However, the safety profile of CaNa2EDTA limits its 
usage, while DMSA lacks appropriate dosing regimen for adults and is less efficacious. High doses of 
CaNa2EDTA increases the risks for lead encephalopathy and fatal cerebral edema.16 Also, CaNa2EDTA 
must be administered at low doses through continuous infusions slowly, in order to ensure safety and 
maximize effectiveness. However, intravenous chelation therapy generally entails five days or more of 
continuous infusion, which may be costly and difficult to manage large populations of people. DMSA is an 
oral chelating agent, approved by the FDA for the treatment of lead poisoning in pediatrics.17, 18 Its use in 
adults is off-label. Extrapolating the dosing regimen for DMSA from pediatrics parameters to adults based 
solely on weight may exceed the maximum daily dosage recommendation, especially in obese adult patients. 
 
Another agent with FDA approval for treatment of internal radionuclide contamination is 
diethylenetriamine pentaacetic acid (DTPA). DTPA has eight potential coordination sites that allow tight 
binding to toxic metals.19, 20 However, due to its 3% bioavailability, DTPA requires intravenous 
administration by medical professionals, which would prevent timely distribution to a large population of 
contaminated individuals. Aiming to improve the oral bioavailability of DTPA, the Jay lab at the University 
of North Carolina has developed a novel synthetic di-ethyl ester analog of DTPA, named C2E2. C2E2 has 
been demonstrated to be bioavailable after oral administration, has low risk for toxicity, and high affinity 
for heavy metals.19, 20 
 
Comparing DTPA, EDTA, and DMSA using established data showed that DTPA is a superior 
chelator for lead than CaNa2EDTA. Based on the structural and functional similarities between DTPA and 
C2E2, it is extrapolated that C2E2 will also have a higher binding affinity for lead than CaNa2EDTA, but 
a lower binding affinity than DTPA. In order to verify this estimation and test the efficacy of C2E2, the 
association constants of C2E2 in human plasma must be first determined in vitro. This is because C2E2 
does not enter red blood cells and its chelation action occurs in the plasma. This information can then be 
combined with pharmacokinetic data in vivo to establish dosing regimens for human.  
 
 
1.2 Specific Aims 
 
Although human lead exposure has decreased in the past few decades since the removal of lead from paint 
and gasoline in the United States, it continues to pose a serious public health concern due to its toxic effects 
on multiple organ systems. Lead is evidenced to be the most harmful to the mental development and 
intelligence of children.4 In addition, attention deficit disorder and irreversible brain damage have been 
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attributed to prolonged or high levels of exposure to lead.4 In adults, chronically elevated blood lead level 
(BLL) can result in hypertension, hyperuricemia, and gout. Because lead has multiple biochemical 
mechanisms for causing toxicity, elevated BLL in adults can also cause neurotoxicity, nephrotoxicity, 
reproductive dysfunction, and cardiovascular complications.21 
 
Developing organ systems in young children are much more vulnerable to lead’s toxic effects, 
which have been observed at much lower blood concentrations than in adults.6 Children younger than the 
age of six have the highest risk of suffering neurological adverse effects from lead exposure, and the effects 
may persist into adulthood. The Centers for Disease Control and Prevention (CDC) estimates that at least 
4 million households in the United States today have children who are exposed to high levels of lead.6 In 
children, the CDC determined that a blood lead level (BLL) above 45 µg/dL warrants chelation treatment; 
however, chelation in adults is only considered at a BLL above 50 µg/dL and with symptoms of lead 
toxicity.12 Lustberg and Silbergeld estimated at least 1.7 million occupationally exposed workers in the 
United States have BLL of 20 µg/dL or greater.21 The authors drew population data from 1976 to 1980 and 
found that a BLL increase from 20 to 29 µg/dL were associated with a 46 percent increase in mortality from 
all causes, a 39 percent increase in mortality from cardiovascular disease, and a 68 percent increase in 
mortality due to cancer, in years subsequently from 1976 through 1992. Therefore, lead toxicity continues 
to pose a serious public health concern, and 1.7 million occupationally exposed workers can be at risk for 
detrimental effects.21  
 
Calcium disodium ethylenediaminetetraacetate (CaNa2EDTA) and meso 2,3-dimercapto-succinic 
acid (DMSA) are two chelating agents currently indicated for treatment of lead poisoning, but both agents 
have limitations.15 CaNa2EDTA has a poor bioavailability of 3-5%. Also, it can cause urinary loss of 
essential minerals. In addition, due to increased risks of lead encephalopathy and fatal cerebral edema when 
used at high doses, CaNa2EDTA is the safest and the most effective when administrated at lower 
concentrations through continuous infusion at slower rates.16,22 However, because intravenous chelation 
therapy for lead toxicity generally requires repeated dosing and extended duration of therapy for five days 
or more, CaNa2EDTA continuous infusion may be inconvenient and costly to treat large populations of 
patients. On the other hand, DMSA is an oral chelator, which is only approved for treatment of lead 
poisoning in pediatrics.23 Its use in adults is off-label. Since the dosing regimen of DMSA is based off of 
pediatric parameters, the maximum recommended dose may be inadequate for adults, especially those who 
are obese. Dosing beyond the maximum recommended daily dose may result in more adverse effects than 
benefits. DMSA is also less efficacious than CaNa2EDTA. The binding affinity of DMSA to lead (log K = 
17.4) is much smaller than the binding affinity of EDTA to lead (log K = 18.04).24  
 
Aiming to improve the oral bioavailability of diethylenetriamine pentaacetic acid (DTPA), a 
chelating agent that is superior at binding lead than CaNa2EDTA, the Jay lab at the University of North 
Carolina has developed a novel synthetic diethyl ester analog of DTPA, called C2E2. C2E2 has high 
affinities for heavy metals and has been shown to be 29% orally bioavailable in Sprague-Dawley rats.19 
Comparing the association constants of DTPA, EDTA, and DMSA to lead, it is expected that C2E2 will 
have a higher binding affinity than either CaNa2EDTA or DMSA for lead. Specifically, C2E2 has been 
shown to possess a smaller association constant for heavy metals than DTPA, but an greater association 
constant than EDTA. Furthermore, the association constant of DTPA to lead is greater than the association 
constant of EDTA to lead by 6.31 fold and that of DMSA to lead by 21.8 fold. Based on existing information 
about the association constants of C2E2 for americium and gadolinium, the association constant of C2E2 
to lead is expected to be three to four times greater than that of EDTA to lead and ten to fifteen times greater 
than DMSA to lead.19, 20 However, this information is unknown. 
 
Based on the pharmacokinetics of C2E2 and the toxicokinetics of lead, we hypothesize that C2E2 
is an effective chelator for removal of lead from contaminated human plasma. The binding affinity of C2E2 
for lead need to be first determined through in vitro experiments in order to calculate an EC50 and an EC90, 
from which a dosing regimen can be calculated for C2E2 chelation therapy. 
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In order to test this hypothesis, the following specific aims are proposed: 
 
Specific Aim 1: Determine the affinity binding constant of C2E2 for lead in human plasma in vitro. 
Specific Aim 2: Generate a dose-response curve based on competitive binding affinities of C2E2 and 
human serum proteins for lead. 
Specific Aim 3: Comparison of C2E2 binding for lead to DTPA binding for lead.  
 
The binding constants and pharmacokinetic parameters determined as part of this study can be 
combined with efficacy data to create a pharmacokinetic-pharmacodynamic model, which can be used to 
predict chelating efficacies at different doses, dosing schedules and durations. We believe that an optimized 
treatment regimen for C2E2 will allow chelation therapy to be efficacious at blood lead levels below 
currently established toxic levels, as well as enable us to extrapolate the therapy regimen to other heavy 
metals currently without adequate and safe oral pharmacological decontamination options. 
 
 
 
2. METHODS 
 
2.1 Affinity Binding Constant of C2E2 for Lead in Human Plasma.  
 
In order to conduct pharmacokinetic modeling of C2E2 for lead using association constants adjusted for 
competitive binding with human plasma components, the ability of C2E2 to chelate protein-bound lead in 
human plasma were quantified experimentally in vitro. Binding of lead to C2E2 versus lead binding to 
protein in plasma samples were measured at three concentrations of lead, 5 µg/dL, 45 µg/dL, and 80 µg/dL, 
and three concentrations of C2E2, 1 µM, 10 µM, and 100 µM.  
 
The method used for investigation were developed and validated in the Jay Lab for chelation of 
radionuclides.19, 20 The binding affinities of C2E2 to americium and gadolinium were determined using this 
method.19 The assumption for this methodological extrapolation was that C2E2 would bind statistically 
significant amount of lead at blood lead concentrations of 5 µg/dL, 45 µg/dL, and 80 µg/dL. These 
concentrations were selected based on current guidelines and recommendations for monitoring and treating 
lead toxicity in adults. 
 
The 80 µg/dL lead concentration was selected because the 2013 AOEC guidelines strongly 
recommends chelation therapy for adults with BLLs greater than or equal to 80 µg/dL.10 If C2E2 effectively 
removed lead at 80 µg/dL BLL, it would show that C2E2 could potentially be superior to CaNa2EDTA and 
DMSA for the treatment of lead poisoning in adults. The 45 µg/dL lead concentration was selected because 
the CDC recommends chelation therapy for children with BLLs greater than or equal to 45 µg/dL.6, 12 If 
C2E2 effectively removed lead at 45 µg/dL BLL, it would further indicate that C2E2 might be superior to 
CaNa2EDTA and DMSA for treatment of lead poisoning in pediatrics. The 5 µg/dL lead concentration was 
selected because the CDC references an elevated BLL as greater than or equal to 5 µg/dL for adults, 
pregnant women, and children, although there is no currently established safe level of lead. 5, 6, 7, 8 However, 
if C2E2 demonstrated adequate removal lead at the reference BLL 5 µg/dL, it could provide additional 
justification for the use of C2E2 prophylactically to prevent lead accumulation in humans. In addition, to 
compare EC50 and EC90 of C2E2 to lead, as calculated by parameters of the regression analysis, it can be 
estimated whether C2E2 is an efficacious chelation agent for lead at specific blood concentrations. These 
results will be used to determine if further investigation of additional blood lead concentrations were needed 
and predict binding efficiency of C2E2 to lead in vivo.  
 
 
 6 
Lead Standard ICP 1000 mg/L (lead (II) nitrate) was diluted with Milli-Q water to prepare stock 
lead solutions, which when added to plasma samples with C2E2 had 0.5 µg/dL, 4.5 µg/dL, and 8 µg/dL as 
final concentrations. These concentrations were used because previous studies indicated that around 99% 
of lead present in the blood are bound to red blood cells. This meant that about 1% of lead in the human 
blood were present in the plasma.25, 26 Solid C2E2 was available from previous chemical synthesis 
performed in the Jay Lab. Solid C2E2 was dissolved in human plasma to contain 1 µM, 10 µM, and 100 
µM of C2E2. Additionally, plasma only served as control since it contained 0 µM C2E2. Pierce Strong 
Cation Exchange Spin Columns were purchased from Thermo Fisher Scientific (Rockfold, IL, USA), and 
Amicon Ultra centrifugal filters with an Ultracel 3K membrane were purchased from Millipore (Billerica, 
MA, USA).  
 
All samples were prepared using fixed volumes of the constituents by combining 7µL of stock lead 
solution and 393 µL of plasma, in which C2E2 solid was dissolved. Immediately after combining the 
constituents, the samples were incubated at 37°C with mild agitation for 60 minutes. After incubation, the 
samples were transferred to Amicon Ultra centrifugal filter devices fitted with Ultracel 3K membranes and 
centrifuged at 14,000 x g for 30 minutes to extract the protein-bound lead fraction. Filtrates from the filter 
devices were then transferred to Pierce Strong Cation Exchange Spin Columns, which were preconditioned 
with 0.8 M ammonium hydroxide. The columns were centrifuged at 2,000 x g for 5 minutes to separate 
positively charged lead ions from the neutrally charged C2E2-bound lead fraction. The positively charged 
lead ions retained on the column were subsequently eluted with 400 µL aliquots of 1 M nitric acid wash 
twice. The free lead fraction was eluted with centrifugation of the columns at 2,000 x g for 5 minutes. The 
lead contents of each fraction were measured by Inductively Coupled Plasma Mass Spectrometry.  
 
Taking variability of the results into consideration and to improve the power, all samples were 
prepared in triplicates to account for statistical variations and human errors during the experimental 
processes. Such errors might include inaccurate pipetting and incomplete transfer of samples.   
 
 
2.2 Dose-Response Curve Based on Competitive Binding Affinities of C2E2 and Human Serum 
Proteins for Lead.  
 
Dose-response curves were constructed by calculating the fraction of total lead bound to C2E2 or bound to 
plasma proteins. Sigmoidal regression profiles were generated by Gauss-Newton non-linear least squares 
regression analysis using SAS 9.3 (SAS, Cary, NC, USA). The regression applied the logistic equation:27 
 𝑦 = 𝑐1 + 𝑒'()*+)	, 
 
where a described the slope as the curve approached the asymptote, b was the inflection point, c was the 
asymptote, and x was the log transformed concentration of C2E2 that corresponded to y, the fraction of 
bound lead. The EC50 and EC90 values were determined by setting y equal to 50% and 90%, respectively, 
of the c term and calculating for x. The same regression analysis was applied to the data for protein-bound 
lead fraction; however, a transformation was applied to yprotein such that, 
 𝑦/ = 	100 − 𝑦2345678	, 
 
where y’ was used for the regression analysis. Subsequent reversal of the transformation produced the final 
binding curves.  
 
Ideally the dose-response curves for the binding of lead by C2E2 and plasma proteins would exhibit 
opposing sigmoidal binding profiles, which would indicate a competitive binding relationship. The logistic 
equation parameters for the C2E2 regression models are summarized under the Results section. The models 
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would ideally achieve goodness-of-fit (R2) greater than 0.92 in all cases. All data were reported as mean ± 
standard deviation from the given number of observations. 
 
 
2.3 C2E2 Binding for Lead Versus DTPA Binding for Lead. 
 
The in vitro experimental method described in Section 2.1 Affinity Binding constant of C2E2 for Lead in 
Human Plasma were repeated three more times, with the following variations. Dose-response curves were 
generated using the same method as described in Section 2.2, Dose-Response Curve Based on Competitive 
Binding Affinities of C2E2 and Human Serum Proteins for Lead, for these three additional experiments.  
 
2.3.1 One Hour Incubation for DTPA. 
Solid DTPA was dissolved in human plasma to obtain 1 µM, 10 µM, 100 µM, and 1000 µM of DTPA. 
Human plasma with 80 µg/dL blood lead concentration (0.0386 µM) were incubated with DTPA at 
concentrations of 1 µM, 10 µM, 100 µM, and 1000 µM at 37°C with mild agitation for 60 minutes. DTPA 
was used in place of C2E2 in the procedure, and all other experimental steps were kept the same.  
 
2.3.2 One Hour Incubation for C2E2. 
Human plasma with 80 µg/dL blood lead concentration (0.0386 µM) were incubated with C2E2 at 
concentrations of 1 µM, 10 µM, 100 µM, and 1000 µM at 37°C with mild agitation for 60 minutes. All 
other experimental steps were kept the same. 
 
2.3.3 Four Hours Incubation for C2E2. 
Human plasma with 80 µg/dL blood lead concentration (0.0386 µM) were incubated with C2E2 at 
concentrations of 1 µM, 10 µM, 100 µM, and 1000 µM at 37°C with mild agitation for 240 minutes. All 
other experimental steps were kept the same. 
 
 
 
3. RESULTS 
 
3.1 Affinity Binding Constant of C2E2 at 5 µg/dL, 45 µg/dL, and 80 µg/dL Blood Lead 
Concentrations. 
 
Three concentrations of C2E2, 1 µM, 10 µM, and 100 µM, were utilized to determine the affinity binding 
constant of C2E2 for lead in human plasma through separation methods. Additionally, 0 µM C2E2 served 
as control. The resulting three fractions, C2E2-bound lead, protein-bound lead, and free lead were collected, 
and the lead content of each fraction was measured by Inductively Coupled Plasma Mass Spectrometry.  
 
Also, three C2E2 regression models, as shown in Figures 1, 2, and 3, were generated and the logistic 
equation parameters are summarized in Supplemental Materials Table 1. From these results, the EC50 and 
EC90 values were calculated for 5 µg/dL, 45 µg/dL, and 80 µg/dL blood lead levels. The EC50 and EC90 
values represent the concentration of C2E2 at which 50% and 90% of maximal binding occurs. The model 
achieved goodness-of-fit (R2) greater than 0.92 in blood lead level at 80 µg/dL. The EC50 and EC90 of C2E2 
for lead at 80 µg/dL blood lead concentration are 0.271 µM and 1.283 µM, respectively. However, the 
models for 5 µg/dL and 45 µg/dL did not achieve expected fits, with R2 0.803 and 0.792 respectively. 
 
Percentage recoveries for 5 µg/dL, 45µg/dL, and 80 µg/dL blood lead concentrations were 804%, 
295%, and 203% respectively, as summarized in Table 1.  
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Table 1. Percent Lead Recovery and Standard Deviations for blood lead concentrations at 5 
µg/dL, 45µg/dL, and 80 µg/dL with C2E2. 
Agent C2E2 C2E2 C2E2 
Concentration (µg/dL) 5 45 80 
Expected recovery (µg/dL) 0.5 4.5 8 
% recovery 804% 295% 203% 
Standard deviation 134.8% 55.2% 31.2% 
 
 
Figure 1. Dose-Response Curve of C2E2 at 5 µg/dL Blood Lead Level. 
 
 
Figure 2. Dose-Response Curve of C2E2 at 45 µg/dL Blood Lead Level. 
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Figure 3. Dose-Response Curve of C2E2 at 80 µg/dL Blood Lead Level. 
 
 
3.2 Affinity Binding Constant of C2E2 at 80 µg/dL Blood Lead Concentration In Comparison to 
DTPA. 
 
Five concentrations of DTPA were utilized to determine the affinity binding constant of DTPA for lead in 
human plasma with 80 µg/dL blood lead level and 1 hour incubation time. Additionally, 0 µM DTPA served 
as control. The resulting fractions were analyzed by ICP-MS, and a regression model was generated, as 
shown in Figure 4. Five concentrations of C2E2 were utilized to determine the affinity binding constant of 
C2E2 for lead in human plasma with 80 µg/dL blood lead level, at 1 hour incubation time and 4 hours 
incubation time. Additionally, 0 µM C2E2 served as control. The resulting fractions were analyzed by ICP-
MS, and regression models were generated, as shown in Figure 5.  
 
All three models did not achieve goodness-of-fit (R2) greater than 0.92. The percentage recovery 
for DTPA was 14.3%. The percentage recovery for C2E2 was 20.5% with 1 hour incubation and 15.7% 
with 4 hours of incubation, as summarized in Table 2.  
 
Table 2. Percent Lead Recovery and Standard Deviations for blood lead concentration at 80 µg/dL with 
DTPA and C2E2, at 1 hour incubation versus 4 hours incubation. 
Agent DTPA 1 Hour C2E2 1 Hour C2E2 4 Hours 
Concentration (µg/dL) 80 80 80 
Expected recovery (µg/dL) 0.8 0.8 0.8 
% recovery 14.3% 20.5% 15.7% 
Standard deviation 2.2% 1.1% 1.8% 
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Figure 4. Dose-Response Curve of DTPA at 80 µg/dL Blood Lead Level with 1 Hour Incubation. 
 
 
Figure 5. Dose-Response Curve of C2E2 at 80 µg/dL Blood Lead Level with 1 Hour Versus 4 
Hours Incubation. 
 
 
 
4. DISCUSSION 
 
4.1 Discussion.  
 
We attempted to fit the data into regression models, but it seems that lead binding is not concentration 
dependent regardless of the C2E2 concentration. The binding profiles for C2E2 at 5 µg/dL, 45 µg/dL blood 
lead levels are inadequate to conclude a binding relationship due to percentage recoveries of over 100%, 
invalid Bmax values, and largely variable standard deviations. For blood lead concentration at 80 µg/dL, 
R2 achieved 0.9516, but a competitive binding relationship cannot be concluded, as percentage recovery 
was 203%. Due to these invalid percentage recoveries, the results are inconclusive for the first three 
experiments. The reason for such percentage recoveries are unclear. These high percentage recoveries also 
lead to more rigorous experimental oversight for repeated experiments, in order to eliminate errors. 
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On the contrary, the experiments subsequently had very low percentage recoveries, for both C2E2 
and DTPA with one hour incubation time (14.3% and 20.5%). Even DTPA, a current lead chelation therapy 
agent, did not achieve an applicable EC50. We suspect that significant amount of lead are lost during the 
initial step of the separation method. We also suspect that lead (II) nitrate may have formed into alterative 
lead species, which are trapped within the Ultracel 3K membrane filters.  
 
To investigate the reason for low recovery, we prolonged the incubation time from 60 minutes to 
240 minutes. Unfortunately, the recovery for C2E2 with four hours of incubation was still low (15.7%). 
Although the percentage recovery was lower with four hours of incubation when compared to one hour of 
incubation, the percentage recoveries for C2E2 differ significantly. The two-tailed p-value for student’s t-
test is less than 0.0001. Also, higher fraction of lead is binding to the ligand fraction in the four-hour C2E2 
experiment, in comparison to the one-hour C2E2 experiment. These differences in recoveries and fraction 
of C2E2-bound lead suggest that longer incubation may have allowed more time for the alternative lead 
species to form and bind to the Ultracel 3K membrane filters. In addition, due poor percentage lead 
recoveries, EC50 and EC90 were not calculated for DTPA nor C2E2 with one- or four-hour incubations. 
 
Because of these low percentage recoveries for both DTPA and C2E2, further experiments are 
performed with higher blood lead concentrations than 80 µg/dL (0.0386 µM). We propose that higher 
concentrations of lead will saturate the system to overcome the loss of lead during the separation steps due 
to the formation of alterative lead species. Results are pending.  
 
Furthermore, future studies may need to repeat these experiments in order to validate the 
experimental method. There may have been calculation errors that resulted in the unreasonably high and 
low percentage recoveries. Also, small errors in measurements in each fraction may have magnified 
calculation errors since the concentration of lead being tested is extremely low. Another limitation of these 
experiments is that human plasma was used to test for C2E2 competitive binding instead of human whole 
blood. In order to extrapolate the results of these experiments into animal models and human subjects, 
further studies are required to determine the differences between C2E2 binding to lead in plasma and in 
whole blood.  
 
 
4.2 Innovation.  
 
The treatment protocols for lead poisoning were established decades ago and have not been updated 
accordingly to reflect modern therapy goals that emphasize safety and convenience for the patient. 
Treatments for lead toxicity may involve oral DMSA, intravenous CaNa2EDTA, or a combination of oral 
and intravenous therapies. The hypothesis is that oral DMSA is effective at removing lead from soft tissues 
and blood, but not effective at chelating lead from bone. The latter is achieved by intravenous CaNa2EDTA. 
However, CaNa2EDTA treatment can result in redistribution of lead to essential organs, most notably the 
brain and liver. Instead of effectively clearing lead from the body, utilization of CaNa2EDTA always carries 
risks for severe adverse effects, such as lead encephalopathy. It is our contention that orally administered 
C2E2, a diethyl ester analog of DTPA, will be safer and more efficacious than intravenous CaNa2EDTA in 
removing lead from bone with minimal risk for lead redistribution to other organs. Also, since DMSA 
cannot effectively chelate lead from bones, we further propose that C2E2 will be more effective than DMSA 
in removing lead from soft tissues considering its greater binding affinity for lead. C2E2 will not only be 
more cost-effective in terms of manufacturing and administration processes compared to injectable 
CaNa2EDTA, but will also allow initiation of chelation therapy at blood lead levels lower than 80µg/dL to 
prevent asymptomatic progression of lead toxicity.  
 
This study represents the initial step and will direct the subsequent phases of a larger investigation. 
The primary innovation of the work described in this report is the construction of a detailed pharmacokinetic 
model that can be used to optimize a C2E2 dosing regimen to safely and effectively remove lead from 
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multi-organ systems without the risk of lead redistribution. The impact of this work is to influence the 
advancement of lead toxicity treatment using far more precise modern technologies in order to bring 
pharmacological protocols up to date. 
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SUPPLEMENTAL MATERIAL 
 
Table 1. Logistic Equation Parameters and EC50 and EC90 of C2E2 for Lead Binding. 
Blood 
Lead 
Level 
(µg/dL) 
Actual 
Lead 
Level 
(µg/dL) 
Coefficient estimates. Estimate (Std. Error) 
R2 EC50 (µM) 
EC90 
(µM) Bmax h Kd (µM) c 
5 0.5 13.760 (21.840) 
0.089 
(0.048) 
3.597e+016 
(9.910e-018) 
0.001 
(0.089) 0.803 3.60e+16 2.07e+27 
45 4.5 2.035 (251.900) 
0.046 
(2.182) 
1.251e+010 
(5.831e+013) 
0.181 
(0.088) 0.792 1.25e+10 4.42e+30 
80 8 0.637 (0.062) 
1.414 
(7.142) 
0.271 
(1.721) 
0.188 
(0.042) 0.952 0.271 1.283 
 
